Published in N Engl J Med on November 30, 2006
Tipranavir in the protease inhibitors arena. Drugs R D (2011) 0.75
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med (2004) 8.11
Cord colitis syndrome in cord-blood stem-cell transplantation. N Engl J Med (2011) 3.83
Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2009) 3.52
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med (2014) 3.48
Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome. N Engl J Med (2013) 3.39
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol (2008) 3.36
Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med (2010) 3.14
Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS (2009) 3.12
Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis (2012) 2.64
Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation (2008) 2.64
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med (2004) 2.30
State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation (2008) 2.17
Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2004) 2.17
Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J Infect Dis (2003) 2.04
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr (2002) 1.98
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood (2010) 1.97
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine (2006) 1.97
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine (2011) 1.88
Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol (2006) 1.88
Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients. JAMA (2010) 1.82
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One (2011) 1.81
Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis (2006) 1.78
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr (2007) 1.73
Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine (2007) 1.73
Diagnostic performance of the (1-->3)-beta-D-glucan assay for invasive fungal disease. Clin Infect Dis (2009) 1.70
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis (2011) 1.67
Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis (2013) 1.63
Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med (2005) 1.55
Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy. Clin Infect Dis (2004) 1.54
High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis (2005) 1.49
Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolate mofetil. Clin Infect Dis (2012) 1.47
Safety and efficacy of initiating highly active antiretroviral therapy in an integrated antenatal and HIV clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr (2008) 1.46
Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol (2010) 1.43
Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci U S A (2011) 1.42
Molecular methods to improve diagnosis and identification of mucormycosis. J Clin Microbiol (2011) 1.41
Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. AIDS (2012) 1.35
Preexposure prophylaxis for HIV--where do we go from here? N Engl J Med (2012) 1.33
Ebola and quarantine. N Engl J Med (2014) 1.32
H1N1 influenza A disease--information for health professionals. N Engl J Med (2009) 1.31
Sex differences in pharmacokinetics and toxicity of antiretroviral therapy. Expert Opin Drug Metab Toxicol (2006) 1.29
(1->3)beta-D-glucan assay positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med (2007) 1.27
Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One (2012) 1.25
Mönckeberg sclerosis revisited: a clarification of the histologic definition of Mönckeberg sclerosis. Arch Pathol Lab Med (2008) 1.25
Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection. AIDS (2013) 1.23
Reactivity of (1-->3)-beta-d-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother (2006) 1.22
Human papillomavirus vaccine--opportunity and challenge. N Engl J Med (2007) 1.22
Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort. AIDS (2013) 1.21
Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis (2012) 1.21
Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. J Virol (2010) 1.18
A biochemical fluorometric method for assessing the oxidative properties of HDL. J Lipid Res (2011) 1.17
Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J Infect Dis (2010) 1.17
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis (2012) 1.17
Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2009) 1.14
Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study. AIDS Care (2011) 1.13
Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. AIDS Care (2011) 1.13
Metabolic disease in HIV infection. Lancet Infect Dis (2013) 1.11
Ebola--an ongoing crisis. N Engl J Med (2014) 1.11
Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis. Biol Blood Marrow Transplant (2012) 1.10
Clinical decisions. Management of skin and soft-tissue infection--polling results. N Engl J Med (2008) 1.09
Fungal infections of the CNS: treatment strategies for the immunocompromised patient. CNS Drugs (2007) 1.07
Calcification of the internal elastic lamina of coronary arteries. Mod Pathol (2008) 1.06
Infectious complications associated with immunomodulating biologic agents. Hematol Oncol Clin North Am (2011) 1.06
Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness. AIDS (2010) 1.06
Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr (2013) 1.05
A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS (2015) 1.05
Infectious complications associated with immunomodulating biologic agents. Infect Dis Clin North Am (2010) 1.05
Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clin Ther (2010) 1.04
Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009. Antimicrob Agents Chemother (2011) 1.04
Respiratory virus detection in immunocompromised patients with FilmArray respiratory panel compared to conventional methods. J Clin Microbiol (2012) 1.03
The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients. Antivir Ther (2004) 1.02
Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin. Clin Infect Dis (2005) 1.02
Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2006) 1.01
Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women. HIV Clin Trials (2007) 1.01
Disseminated trichosporonosis caused by Trichosporon loubieri. J Clin Microbiol (2003) 1.00
Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. Cancer Invest (2007) 0.99
Fungal brain infections. Curr Opin Neurol (2008) 0.98
Management of oral infections in cancer patients. Dent Clin North Am (2008) 0.97
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. Clin Infect Dis (2009) 0.96
Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax. J Infect Dis (2010) 0.96
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study. Antimicrob Agents Chemother (2011) 0.96
Determinants of participation in HIV clinical trials: the importance of patients' trust in their provider. HIV Clin Trials (2009) 0.95
Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men. J Clin Pharmacol (2011) 0.95
The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment. PLoS One (2012) 0.95
Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Biol Blood Marrow Transplant (2006) 0.94
A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDS (2012) 0.94
Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys. Vaccine (2009) 0.94
Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy. J Clin Lipidol (2008) 0.94
Assessing sexually transmitted infections in a cohort of women living with HIV/AIDS, in Rio de Janeiro, Brazil. Int J STD AIDS (2006) 0.93
When to start antiretroviral therapy--ready when you are? N Engl J Med (2009) 0.93
Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis (2013) 0.92
Clinical practice. Postexposure prophylaxis for HIV infection. N Engl J Med (2009) 0.92
HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL. Lipids Health Dis (2011) 0.92
Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant (2010) 0.92